DURECT (DRRX) Competitors $1.91 +0.01 (+0.53%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. FENC, PRQR, ALLO, TKNO, TVRD, ALEC, CRGX, AVTE, SOPH, and ACIUShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Adherex Technologies (FENC), ProQR Therapeutics (PRQR), Allogene Therapeutics (ALLO), Alpha Teknova (TKNO), Tvardi Therapeutics (TVRD), Alector (ALEC), CARGO Therapeutics (CRGX), Aerovate Therapeutics (AVTE), SOPHiA GENETICS (SOPH), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors Adherex Technologies ProQR Therapeutics Allogene Therapeutics Alpha Teknova Tvardi Therapeutics Alector CARGO Therapeutics Aerovate Therapeutics SOPHiA GENETICS AC Immune DURECT (NASDAQ:DRRX) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Do insiders & institutionals believe in DRRX or FENC? 28.0% of DURECT shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 3.2% of DURECT shares are owned by insiders. Comparatively, 11.8% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is DRRX or FENC more profitable? Adherex Technologies has a net margin of -35.05% compared to DURECT's net margin of -96.19%. Adherex Technologies' return on equity of 0.00% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets DURECT-96.19% -259.16% -71.78% Adherex Technologies -35.05%N/A -23.30% Which has higher valuation and earnings, DRRX or FENC? Adherex Technologies has higher revenue and earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDURECT$2.03M29.21-$8.32M-$0.10-19.10Adherex Technologies$47.54M4.89-$440K-$0.51-16.39 Which has more volatility and risk, DRRX or FENC? DURECT has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Does the media prefer DRRX or FENC? In the previous week, DURECT had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 11 mentions for DURECT and 9 mentions for Adherex Technologies. DURECT's average media sentiment score of 0.55 beat Adherex Technologies' score of 0.06 indicating that DURECT is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DURECT 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate DRRX or FENC? Adherex Technologies has a consensus price target of $13.33, indicating a potential upside of 59.49%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DURECT 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Adherex Technologies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryAdherex Technologies beats DURECT on 11 of the 17 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59M$2.75B$5.67B$9.83BDividend YieldN/A1.78%3.79%4.08%P/E Ratio-19.1021.8930.5825.12Price / Sales29.21723.29463.91116.12Price / CashN/A177.1637.4059.05Price / Book17.365.079.096.18Net Income-$8.32M$31.61M$3.25B$264.89M7 Day Performance2.14%5.04%4.76%2.66%1 Month Performance260.24%6.25%6.72%3.05%1 Year Performance66.09%12.82%30.51%25.05% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.8421 of 5 stars$1.91+0.5%N/A+42.9%$59M$2.03M-19.1080Earnings ReportShort Interest ↓FENCAdherex Technologies2.3519 of 5 stars$8.25-1.0%$13.00+57.6%+60.0%$231.69M$47.54M-16.1810News CoverageEarnings ReportAnalyst ForecastPRQRProQR Therapeutics2.3152 of 5 stars$1.89-12.9%$8.00+323.3%-9.8%$228.31M$20.46M-4.11180Gap DownHigh Trading VolumeALLOAllogene Therapeutics3.034 of 5 stars$1.03-1.0%$8.44+719.8%-52.4%$227.48M$20K-0.84310Trending NewsEarnings ReportGap UpTKNOAlpha Teknova2.4052 of 5 stars$4.41+4.3%$10.00+126.8%+29.4%$226.05M$37.74M-10.50240TVRDTvardi TherapeuticsN/A$24.13+0.9%$64.25+166.3%N/A$223.96M$7.14M0.0080News CoveragePositive NewsEarnings ReportALECAlector3.9619 of 5 stars$2.23+3.7%$4.17+86.8%-49.4%$217.61M$100.56M-1.92270High Trading VolumeCRGXCARGO Therapeutics2.3563 of 5 stars$4.48-0.2%$15.40+243.8%-73.0%$217.16MN/A-0.97116Positive NewsAVTEAerovate TherapeuticsN/A$7.49+2.3%N/A-87.8%$217.10MN/A-2.5120Gap UpHigh Trading VolumeSOPHSOPHiA GENETICS3.0013 of 5 stars$3.01-5.3%$8.00+165.8%+0.0%$214.90M$65.17M-6.84520Short Interest ↓Gap DownACIUAC Immune1.8199 of 5 stars$2.07-3.3%$12.00+479.7%-35.3%$214.88M$31.02M-3.57140 Related Companies and Tools Related Companies FENC Competitors PRQR Competitors ALLO Competitors TKNO Competitors TVRD Competitors ALEC Competitors CRGX Competitors AVTE Competitors SOPH Competitors ACIU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access